Navigation Links
Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
Date:9/24/2010

THOUSAND OAKS, Calif., Sept. 24 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution.  The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.  The products are indicated for the treatment of anemia related to HIV therapy, chronic renal failure, and chemotherapy.

Evaluations by Amgen and Centocor Ortho Biotech Products, L.P. found a low potential to impact patients who may have received the affected product.   The potential serious adverse events resulting from the use of a sterile injectable product with particulates by the intravenous route include embolic, thrombotic and other vascular events (e.g., phlebitis), and by the subcutaneous route include foreign body granuloma, local injection site reactions, and increased immunogenicity.  To date, there have been no complaints or adverse events reported which can be directly attributed to the presence of glass lamellae.  

The affected product lot numbers and expiration dates are included in the table below and at www.epogen.com and www.procrit.com.

Adverse events related to EPOGEN should be reported to 1-800-77-AMGEN. Adverse events related to PROCRIT should be reported to 1-800-547-6446. Consumers with questions regarding this recall can contact Amgen at 1-800-77-AMGEN (open 24 hours per day, 7 days per week) or Centocor Ortho Biotech Products at 1-800-547-6446 (open 24 hours per day, 7 days per week).

Consumers should contact their p
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final ... (CDC) Contact Lens Health Week, 1-800 Contacts is sharing ... found that contact lens wearers who do not properly ... risk for eye infections. Most contact ... lenses, but a clean lens case is sometimes overlooked.  ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... March 16, 2011 Unilife Corporation ("Unilife" or the "Company") ... its Chief Executive Officer, Alan Shortall, has made open market ... the Australian Stock Exchange (ASX). Mr. Shortall, who ... 632,713 CDIs at an average price of A$0.795 (US$0.80) per ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... CMED ), a leading ... company, today announced that it ... following investor conferences and events: ...
Cached Medicine Technology:Unilife CEO Makes Open Market Purchase of A$500,000 in Company's Publicly Traded Shares 2Unilife CEO Makes Open Market Purchase of A$500,000 in Company's Publicly Traded Shares 3China Medical Technologies to Meet Investors 2
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly ... for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, ... track product movement from beginning to end. , Businesses benefit greatly from having the ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... Rochester, NY (PRWEB) , ... August 28, 2015 , ... ... injectable, Kybella™. It is the first and only nonsurgical product approved by the ... Dr. Vito Quatela and Dr. William Koenig are among ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... CEPH ) announced today that the underwriters ... aggregate principal amount of 2.50% convertible senior subordinated notes ... to purchase $65 million of additional notes, bringing the ... $500 million. Completion of the notes offering, including the ...
... Ontario Systems, a leading provider of revenue cycle ... management and health care industries, today announced that ... the company and will lead its debt management ... direction of all Ontario debt management solutions, including ...
... tied to this nutritional deficit , , FRIDAY, May ... may contribute to cancer development, U.S. researchers have found. ... communication among cells due to, among other things, low ... an epidemiologist at the Moores Cancer Center at the ...
... findings could alter treatment methods, , , THURSDAY, May 21 (HealthDay ... amputated because of diabetes were reduced by 36 percent when ... to lower their blood fat levels, new research has found. ... who took either 200 milligrams of fenofibrate or a placebo ...
... Patients under 44 were three times more likely to die, ... Younger men diagnosed with advanced prostate cancer don,t live as ... study finds. , "Overall, young men with prostate cancer do ... prostate cancers did substantially worse than old men with similar ...
... May 22 The National Board of Certification for ... performance exam that will be part of the testing ... weeks, 300 interpreters will "test the test" designed to ... and skills in real-life medical interpreting scenarios. This process ...
Cached Medicine News:Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 2Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 3Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 4Health News:Cutler to Direct Debt Management Product Strategy at Ontario Systems 2Health News:Drug May Lessen Amputation Risk for Diabetics 2Health News:Advanced Prostate Cancer Deadlier in Younger Men 2Health News:Advanced Prostate Cancer Deadlier in Younger Men 3Health News:National Medical Interpreter Certification Testing Enters Pilot Phase 2Health News:National Medical Interpreter Certification Testing Enters Pilot Phase 3
Desmarres Lid Retractor thin solid blades. Size 2....
... of the AMO Prestige System marked ... The combination of safety with high-performance ... of fluidic conditions in the in ... Pump" orchestrates the reaction and interaction ...
Highly versatile, efficient, compact and accurate digital readout display....
... phaco system has all the features of ... dependable engineering means minimal maintenance. Small, light ... site to site. Lowest cost reusable tubing ... No longer is there a price objection ...
Medicine Products: